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Supraventricular tachyarrhythmia with a rapid ventricular
response is frequently found early after cardiac surgery (I).
Tachycardia not only increases cardiac work and myocardial
oxygen demand, but also decreases myocardial perfusion
and oxygen supply and thus may rapidly compromise the
patient's condition. Therefore, tachycardia itself warrants
prompt treatment in the critical period after cardiac surgery .
Supraventricular tachyarrhythmia early after cardiac sur-
gery is usually transient and episodic (1,2), and the patient's
condition in this critical postoperative period can change
rapidly and unpredictably . Therefore, only those drugs that
have a short duration of action and can be rapidly titrated are
suitable for treating patients 106 critical period . Conven-
tional beta-adrenergic blocking agents with a longer duration
of action, such as propranolol (4 to 6 h), would not be the
ideal agent in this period . Esmolol, a cardioselective beta-
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fioned complications, a new dosing regimen was constructed . The
initial infusion rate of esimolol was set at 150 or 100 PgNg PW mitt,
depending on the patient's age and blood pressure. When the
desired heart rate was achieved, the initial infusion rate was
reduced to the maintenance Infusion rate to maintain the thera-
pe"Ofic effect
[Maintenance infusion rate = Initial inkslon rate x
(1 - where t is the time period In minutes required by
the initial Inihsion of esmolol to achieve the therapeutic effect) .
With this new dosing regimen, tachycarilia in most patients (9 of
11) could be controlled within 10 min, and no one experienced the
side effect of hypotension. The maintenance Infusion rate of
lmedme M to control supraventricular tachyarrhydimis in
our patients was only 73 :t 42 p&g per min (mean :t SD), much
that nOW in western reports .
Conclusions. 11M dosing regimen for esmolol Infusion recom-
mended in woUrn studies is nd suitable for Chinese Patients . In
this reltort we proposse a new dosing regimen for esmolol h9hsion
that is both SaAfe and rapid In the treatment of supraventricular
by hyth In Chinese patients .
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blocker with an ultrashort half-life, seems to be able to
overcome these problems.
However, there have been no reports of clinical experi-
ence with esmolol in Chinese patients . In this report, we
discuss our initial clinice: trial of esmolol in the treatment of
supraventricular tachyarrhythmia early after cardiac surgery
in Chinese patients, the difficulties that we encountered in
our trials and our use of a new dosing regimen to overcome
these difficulties .
Methods
This study was performed under the supervision of the
Council of Clinical Pharmacy Trials, National Taiwan Uni-
versity Hospital .
Study patients. All patients were of Chinese descent
undergoing cardiac surgery . Digoxin and beta-blocker ther-
apy was routinely discontinued 24 h before the cardiac
operation. Anesthesia was induced with diazepam, fentanyl
and pancuronium bromide and maintained by balanced an-
esthesia of isoflurane inhalation and fentanyl and pancuro-
nium bromide. A Swan-Ganz catheter was inserted through
the right internal jugular vein. Cardiopulmonary bypass was
0735-1097/941$7.00
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Table 1 . Clinical Characteristics of Six Patients Receiving the Standard Occidental Dosing Regimen for Esmolo) Infusion
maintei :,eJ by pulsatile flow with a roller pump . During
bypass, the activated clotting time was maintained between
IN and 6M) s with heparin . Operations were performed with
moderate hypothermia (27 to 28°C) and partial hemodilution
(hematocrit 25% to 30%). Cardiac arrest was obtained by
potassium cardioplegic solution, and the arrested heart was
topically cooled .
Exclusion criteria. Patients with the following criteria
were excluded from the study : systolic blood pressure
2!10 mm Hg less than the preoperative value ; sick sinus
syndrome ; any degree of atrioventricular (AV) block ; ven-
tricular arrhythmia requiring drug therapy ; cardiac pump
dysfunction (cardiac index <2 .0 liters/min
per
m2) or the
need for catecholamine i0ision to maintain hemodynamic
stability ; hepatic dysf.;nction (albumin <2 .5 glal, bihrubin
>2 mg/dl, prothrombin time prolongation >4 s) ; renal dys-
function (creatinine >1 .5 mg/dl); pulmonary dysfunction
(chronic obstructive pulmonary disease or asthma) and age
< 16 years .
Inclusion criteria . When supraventricular tachyarrhyth-
mia with a rapid ventricular response (ventricular rate > 110/
min) was found during a patient's stay in the intensive care
unit, the possible etiologies of pain, hypoxemia, hyper-
capnia, hypovolemia, and other conditions were first ex-
cluded . After these exclusions, patients with persistent rapid
ventricular rates were treated with esmolol infusion (Du
Pont Pharmaceuticals, Manati, Puerto Rico) . Therapeutic
response was def .-zd as a-20% decrease in heart rate,
reduction in heart `ate to < 100/min or conversion to normal
sinus rhythm . Except for Patient 3 in the standard dosing
regimen group, all patients were studied within 2 days after
cardiac surgery and did not receive digoxin in the postoper-
ative period before the esmolol infusion .
Results
Standard dosing regimen for esmolol (repeated loading
infusion with stepwise increments) . Treatment of patients
with supraventricular tachyarrhythmia was initiated with a
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*Supraventricular tachycardia occurred on day 4 after surgery, and the patient received two injections of digoxin (0
.25 mg/dose) before esmolol infusion
without adequate response . Afib = atria) fibrillation
; API = atria) flutter ; ATN = acute tubular necrosis ; AV = atrioventricular
; BP = blood pressure ; CABG =
coronary artery bypass graft ; CAD = coronary artery disease ; DAM = dissecting aortic aneurysm (De Bakey type I)
; DVR = double-valve replacement
(including aortic and mitral valve) ; Dx = diagnosis ; F = female ; HR = heart rate ; M = male
: MVR = mitral valve replacement ; NSR = normal sinus rhythm ;
OP = operative procedure ; Pt = patient ; RVD = rheumatic valvular disease
; VF = ventricular fibrillation,
loading infusion of 500,ug/kg body weight per min of esmolol
(according to the dosing regimen provided by Du Pont
Pharmaceuticals [Product Information, Breviblock, 1991])
and was administered for I min, followed by a 4-min
maintenance infusion of 50 Ag/kg per min . If an adequate
therapeutic response was not observed within 5 min, the
same loading dosage was repeated and followed with a
maintenance infusion increased to 100 mg/kg per min . This
titration procedure was continued, with the loading infusion
repeated (500 pyAg per min) for I min and the maintenance
infusion increased by an increment of 50 ag/kg per min,
maintained for 4 min . As the desired heart rate or a safety
end point (e .g ., hypotension) was approached, the loading
infusion was omitted, and the incremental dose of the
maintenance infusion was reduced from 50 to X25 Ag1kg per
min and then kept at the maintenance infusion rate after-
ward. This dosing regimen for esmolol infusion in the
treatment of supraventricular arrhythmia has been reported
to give good results by many investigators (3,4) .
However, in our clinical trial, acute hypotension with
systolic pressure <80 mm Hg occurred in all six patients
after the 1st min of the loading infusion of esmolol (500 Ag1kg
per min for I min) . The clinical characteristics of the patients
before esmolol infusion are shown in Table 1 . Esmolol
infusion was terminated in all patients because of the acute
hypotension . In addition, complete AV block with escape
junctional rhythm occurred in Patient 2, whose cardiac
rhythm changed back to atria] fibrillation a few minutes later
without specific treatment . In Patient 3, ventricular fibrilla-
tion occurred during the hypotensive episode . He was
successfully resuscitated with direct current shock and epi-
nephrine injection, but this was complicated by acute renal
failure from which he gradually recovered after 4 weeks of
peritoneal dialysis . In other patients, after termination of the
esmolol infusion, the hypotensive episodes resolved without
obvious sequelae .
Dosing regimen for initial slow infusion with stepwise
increment. To avoid acute hypotension after the esmolol
loading infusion, we omitted the loading infusion and initi-
Pt
No .
Age (yr)/
Gender Dx OP
Before Esmolol Infusion
Complication
Cardiac
Rhythm
HR
(beatsiminl
BP
(mm Hg)
1 65, 11 4. CAD CABG AM (21 : 1) 150 127/53
2 69/M RVD MVR AS 150 150/60 AV block
3 0 61/M
CAD
CAD
CABG
CABG Afib 160 110/70 VF, ATN
4 31/M DAM Bentall procedure NSR 117 146/75
5 55/F RVD DVR Alb 140 154180
6 4?JM RVD MVR AW 130 WW70
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ated esmolol infusion at a rate of 25 pg/kg per min
. If the
desired heart rate was achieved by this maintenance infu-
sion, the infusion rate was maintained . If the desired heart
rate could not be achieved by the initial infusion within
.36 min, the infusion rate was increased by an increment of
25 pg/kg/min, and clinical response was observed for an-
other 36 min
. This procedure was repeated until the thera-
peutic end point was approached . (As assessed by pharma-
cokinetic variables, a steady state drug level by continuous
infusion could be assumed only after 4 half-lives of the drug .
The elimination half-life of esmolol is 9 min ; therefore,
36 min was chosen for our protocol .)
Although this dosing regimen was completely safe, it took
a long time to reach a therapeutic end point in some patients .
Because the time needed could be too long to be acceptable
in the critical care setting, this dosing regimen was given up
after trials in only a few patients .
New dosing men for esmolol Infusion
. The new dosing
regimen was constructed by a one-compartment first-order
elimination pharmacokinetic model. If esmolol was infused
into a compartment with volume V at a constant rate I and
eliminated from the compartment with the first-order elimi-
nation kinetic constant K, then the change in concentration
C of esmolol with time t (in min) can be represented by the
differential equation dC/dt = IN - K X C. Assuming that
there was no esmolol in the compartment before esmolol
infusion, then the concentration of esmolol in the compart-
ment can be obtained by solution of the following differential
equation:
C = KV(i - e ® 1') . I I l
From equation 2, it can be inferred that steady state levels of
esmolol infusion (Cn) were directly proportional to their
infusion rates :
Cn = I/KV, t 121
Because there is a relation between half-life (t 112) and the
first-order elimination kinetic constant (K), K = 0.693/t 112 ,
where the half-life of esmolol is known to be 9 min (5), we
can then obtain equation 3,
C = Cp(l -
e-°'°77'),
13)
and the concentration of esmolol at a particular instant can
be expressed as the percent steady state level achieved with
the given infusion rate (Fig . 1) .
In our new dosing regimen, when a patient with supra-
ventricular tachyarrhythmia was to be treated by esmolol
infusion, the infusion was initially set at a higher rate. When
the desired heart rate was achieved, the time needed by the
initial infusion to achieve this therapeutic effect was re-
corded . The serum level at that time was assumed to be that
level needed to maintain the desired heart rate, and the
percent steady state level it represented at that time could be
calculated. Because steady state levels of esmolol infusion at
Figure 1 . One-compartment first-order elimination pharmacokinetic
model of esmolol infusion (see equations I to 3 in text), CP` _
concentration of esmolol at steady state .
different infusion rates were directly proportional to the
infusion rates themselves, the maintenance infusion rate
needed to maintain the desired serum level could be obtained
by the initial infusion rate multiplied by that percent . The
changes in serum level of esmolol in our new dosing regimen
are shown in Figure 2 . Although the new dosing regimen
involved complex calculations, the rule of thumb was sim-
ple. If the times needed by the initial infusion to reach the
therapeutic end point were 5, 10 and 15 min, then mainte-
nance infusion rates were about one-third, one-half and
two-thirds the initial infusion rate . Initial esmolol infusion
rates of 150 or 100 pg/kg per min were arbitrarily chosen for
our new dosing regimen according to the patient's age and
blood pressure . If the patient was young and hypertensive,
the initial infusion rate was set at 150 g per min ; other-
wise it was set at 100 µg/kg per min . Eleven patients received
the new dosing regimen for esmolol infusion to treat supra-
ventricular tachyarrhythmia early after cardiac surgery .
Their clinical data are shown in Table 2 . Blood pressure was
well maintained in all patients, and no one experienced
Figure 2. Change in serum level of esmolol in the new dosing
regimen for esmolol infusion . The serum level of esmolol increased
along line X with the initial infusion rate . At point A, the desired
heart rate (HR) was achieved, and the initial infusion rate was
reduced to the maintenance infusion rate, which then maintained the
serum level to keep the desired heart rate .
JACC Vol . 23, No . 2
February 1994:302-6
. x
direr! MR	 Y
J
time
,ACC M21NY7
February 1994:302-6
hypotension . The average maintenance infusion rate needed
in our patients was 73 ± 42 gg/kg per min (mean ± SD), and
heart rate significantly decreased from 134 ± 20 to 100 ±
12 beats/min (p < 0.01 by paired i test) . In 9 (82%) of eleven
of the patients, supraventricular tachyarrhythmia could be
controlled within 10 min of the initiation of esmolol infusion .
Discussion
Esmolol has the advantages of rapid onset of action (6),
ultrashort duration of action (half-life 9 min) (5), metabolism
by esterase to inactive metabolite in red blood cell cytosol,
and its metabolism is not affected by renal (7) or hepatic (8)
disease . Complete dissipation of side effects occurred within
20 to 30 min after termination of esmolol infusion (6), and
this is an important advantage of esmolol over propranolol
(9). Therefore, esmolol seems to be an ideal agent to treat
supraventricular tachyarrhythmia in the critical period after
cardiac surgery . Gray et al. (10) studied esmolol for rapid
control of heart rate in postoperative supraventricular tach-
ynrrhythmia . In their study, esmolol was given by loading
infusion (500 pg/kg per min x 1 min), followed by a main-
tenance infusion (25 to 300 µg/kg per min) titrated according
to heart rate and blood pressure . In 19 of 24 patients, heart
rate was reduced by 20%, and conversion to sinus rhythm
occurred in 5 of I I patients with atrial flutter or fibrillation .
Asymptomatic hypotension occurred in 13 patients, with
drug withdrawal required in only 2 patients . In comparison,
with the same dosing regimen, the side effect of hypotension
seemed to be more prevalent and severe in our patients .
There are several reasons for this finding .
Increased sensitivity to beta-blockers in Chinese patients .
Zhou et al. (11) reported that Chinese men had a greater
sensitivity than white men to the effects of propranolol on
heart rate and blood pressure . They showed that the plasma
concentration of nropranolol required to produce a 10%
reduction in mean blood pressure was 748 ± 7 nmol/liter in
white patients but only 73 ± 5 nmollliter in Chinese patients .
Venter and Joubert (12) reported that black subjects in South
KO AND CHU
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Table 2
. Clinical Characteristics of I I Patients and Their Responses to "New" Dosing Regimen for Esmolol Infusion
AAA = abdominal aortic aneurysm ; AS = degenerative aortic Menosk GR = graft repair t = time period (in min required by initial infusion of esmolol to
achieve therapeutic effect ; other abbreviations as in Table I .
Africa were less sensitive to intravenous propranolol than
were white subjects . It seems that among different ethnic
groups, Chinese subjects are the most sensitive to proprano-
lol. Chinese patients may be more sensitive to all beta-
blockers, including esmolol . However, the mechanism of the
increased sensitivity in Chinese patients requires further
investigation . Because acute hypotension occurred in our
patients after only I min of the esmolol loading infusion,
pharmacokinetic factors do not seem to account for the
phenomenon. Beta-receptors on the lymphocyte membranes
have been found to be correlated with cardiac sensitivity
(i3) . Both receptor density and the dissociation constant at
the beta-receptors on the lymphocyte are similar in Chinese
and white subjects (11) . Thus, it seems that the difference in
patient responses occurs distal to the receptor itself . How-
ever, it should be noted that beta-receptors on the lympho-
cyte are exclusively the beta
2
subtype, whereas the cardiac
beta-receptors are largely beta, . Further study is needed to
settle these problems .
Uneven drug distribution in the body . The distribution
half-life of esmolol averages 2.03 min, and its apparent
volume of distribution averages 3 .43 liter/kg and four times
the volume of the central compartment (6) . Therefore, imme-
diately after a rapid loading infusion of esmolol, the drug was
not evenly distributed in the body, and the peak serum level
became much higher than expected . The fluent perfusion
organs, such as the heart, overreact to the beta-blockade
effect. The acute hypotension experienced by our patients
occurred because the resultant hemodynamic changes Were
too rapid for us to respond .
Increased susceptibility to myocardial depression hnmedi-
ately after cardiac surgery. The myocardium immediately
after cardiac surgery is more susceptible to depression by
beta-blockers because of the effects of surgical damage,
hypothermia, cardioplegic solution among others . The dos-
ing regimen for slow initial infusion with a small increment
was safe but might unduly prolong the time required to reach
the therapeutic end point in some patients. Therefore, this
dosing regimen was still impractical for the treatment of
Age (yr)/
Gender Ds OP
Initial 0 :,t
(pglkg body wt per min)
t
(min)
Maintenance Dose
(tg/kg body wt per min)
Cardiac
Rhythm
HR
(beats/min)
491F RVD MVR 150 9 75 Afib NSR 113 -> 69
511M CAD CABG 150 to 80 NSR NSR 129-* 105
7011M CAD CABG I00 4 25 AF] NSR 168- 114
49/F RVD MVR 150 5 so Afib Afib 155 07
611M CAD CABG 150 5 50 NSR NSR 137 20
61/M AAA GR 150 36 150 Afib Afib IT-,
61/M AS AVR 150 10 80 NSR - NSR 117 - 96
70/M CAD CABG 100 9 50 Afib - NSR 160- 110
66/F RVD AVR 150 4 40 NSR NSR 119-91
621M CAD CABG 150 5 50 NSR NSR III -~ 95
72/M CAD CABG 150 36 150 NSR NSR 129- 100
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critically ill patients . To find a better dosing regimen, we
constructed a one-compartment pharmacokinetic model of
esmolol (Figure 1) .
Although this model was simplified, it gave results that
were compatible with actual experimental results . Sum et al .
(5) reported that the steady state serum level of esmolol was
approximately proportional to the infusion rate of the drug in
the usual therapeutic range (50 to 400 pg/kg per min) . In their
experiment, steady state serum levels of esmolol were 0 .164,
0.569 and 1.59 pg/ml, respectively, after infusion at rates of
50, 150 and 400
	
g per min .
In our model, serum levels of esmolol at 10 and 15 min
after constant esmolol infusion were 54% and 68% of steady
state level . Therefore, if the initial infusion rate of esmolol
was set at 1 .5 to 2 times the theoretic maintenance infusion
rate needed to maintain the therapeutic serum level, it could
be reached within 10 to 15 min after the start of the initial
infusion . The time interval of 10 to 15 min is both long
enough for the even distribution of esmolol throughout the
body and for observation of and response to its clinical
effects and short enough to be acceptable in the critical care
setting.
Gray et al . (10) reported that at an average dose of 139 ±
83 per min (mean ± SD) by intravenous infusion,
esmolol reduced mean heart rate from 130 ± 15 to 99
15 beatstmin in the treatment of supraventricular tachyar-
rhythmia after cardiac surgery, and that all patients experi-
enced a 15% reduction in heart rate at a maintenance dose
<_ 150 p g/kg per min . However, in our limited clinical trial the
maintenance infusion rates needed to control ventricular rate
in supraventricular tachyarrhythmia were only 73 ± 42 pg/kg
per min (mean ± SD) . This is statistically less than that
reported by Gray et al . (p < 0.01 by a one-tailed Student
t
test) . Because we wanted the initial infusion rate to be 1 .5 to
2 times the maintenance infusion rate in our new dosing
regimen, an initial infusion of esmolol at a rate between 100
and 150 per min seemed to be a good choice . There-
fore, in supraventricular tachyarrhythmia occurring early
after cardiac surgery in young, strong, hypertensive Chinese
patients, the initial infusion rate of esmolol was set at
150 g/min. Conversely, in weak, nonhypertensive, el-
derly Chinese patients, the initial infusion rate was set at
100 pgtkg per min for the sake of safety . When the thera-
peutic effect was achieved, the initial infusion rate was
reduced to the maintenance infusion rate to maintain the
therapeutic effect (Fig . 2). After adoption of this new es-
molol infusion regimen, our patients no longer experienced
the side effect of acute hypotension observed in our initial
trial . However, we could still control heart rate in most
patients within 10 to 15 min after initiation of the esmolol
infusion, a time interval acceptable for most patients in
intensive care units .
Conclusions. In the treatment of supraventricular tachy-
arrhythmia, the dosing regimen for esmolol infusion recom-
mended in western published reports was intolerable in
Chinese patients . We thus proposed a new dosing regimen
for esmolol infusion that was both safe and rapid in treating
supraventricular tachyarrhythmia in Chinese patients .
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